TMEM259

Across TCGA pan-cancer cohorts, TMEM259 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM259 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TMEM259 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM259 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, STAD, and LGG are the cancer types where TMEM259 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.165	0.924	<.001	36	view →
STAD	OS	Median	All	0.250	0.729	.028	12	view →
LGG	OS	Median	All	0.208	0.896	<.001	12	view →
SCLC	OS	Median	All	0.205	0.659	.008	6	view →
COAD	DFS	Median	All	0.240	0.696	.030	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.219	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM259–BRCA (OS)

Open the BRCA breakdown →